ASCO 2023 | Treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and micro-metastasis

Nadeem Bilani, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and lymph node micrometastasis. The goal is to gather prospective data to determine if chemotherapy can be spared for these patients, considering its impact on fertility and toxicities. Conversations with patients about chemotherapy’s potential to reduce disease recurrence but not necessarily prolong lifespan are important for informed decision-making. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.